Pancreatic Adenocarcinoma Clinical Trial
— OBTCPANOfficial title:
Interobserver Variability In The Assessment Of Vascular Invasion In Pancreatic Cancer
NCT number | NCT03673423 |
Other study ID # | OBTCPAN |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | September 5, 2018 |
Est. completion date | May 5, 2019 |
Assess the degree of vascular involvement is crucial in the diagnostic and therapeutic
work-up of pancreatic cancer. NCCN resectability classification is used to stratify patients
(in resectable, borderline resectable and non resectable) and is based on contrast-enhanced
CT scan images. Unfortunately evaluation of imaging tests may rely on some degree of
subjective interpretation by observers implying a fundamental variation in patient's
treatments and an irreproducibility of different center study results.
This is a multicenter diagnostic study on interobserver agreement on the resectability of
pancreatic cancer based upon NCCN criteria.
The primary aim of the study will be the assessment of interobserver variability to define
vascular invasion and resectability status on CT scans (according to the last version of the
NCCN Classification).
One hundred and thirty eight consecutive patients, able to produce an informed consent, from
18 years of age, with a non-metastatic pancreatic adenocarcinoma assessed by a
contrast-enhanced high-quality CT scan will be enrolled.
69 CT scan studies provided by the centers involved (High volume for pancreatic surgery) will
be randomly selected from a pool of 138 of the patients that meet the inclusion criteria.
Each study will be independently reviewed by a senior radiologist and a senior surgeon of
each center, blinded to patient's clinical history and CT scan report, using NCCN definition
of respectability status. A CFR will be filled during the review and send to the study
coordinator. The data will be than centrally analyzed to asses interobserver agreement The
enrolment phase will last 6 months and the whole study will last 8 months.
Status | Recruiting |
Enrollment | 138 |
Est. completion date | May 5, 2019 |
Est. primary completion date | March 5, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age > 18 years - Non-metastatic pancreatic adenocarcinoma - Availability of contrast enhanced CT scan with adequate quality. Section thickness must be <3 mm, according to NCCN recommendations - Pathological confirmation of pancreatic adenocarcinoma by cytology/histology is not required at the time of enrolment, but it is needed before including the CT scan in the pool of exams to be evaluated. - Signed informed consent Exclusion Criteria: - Evidence of metastatic disease - Inadequate quality CT scan (non-respecting the NCCN recommendations) - Absence of cytology/histology confirmation - Refusal to participate in the study |
Country | Name | City | State |
---|---|---|---|
Italy | Ospedale San Raffaele | Milano |
Lead Sponsor | Collaborator |
---|---|
Ospedale San Raffaele |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of interobserver variability to define vascular invasion and resectability status on CT scans | The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification). | Eight months | |
Secondary | Identification of disagreement causes and proposal of a new classification system | In case of significant low agreement (K < 0,5), causes of disagreement will be assessed and a new classification of vascular involvement will be proposed to reduce the disagreement. The new classification will be validated on the remaining 69 CT scans | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Completed |
NCT01959672 -
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Not yet recruiting |
NCT06026943 -
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer
|
N/A | |
Completed |
NCT03054987 -
Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction
|
N/A | |
Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
Recruiting |
NCT02072616 -
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
|
Phase 3 | |
Completed |
NCT02174887 -
Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT03703063 -
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
|
Phase 1 | |
Terminated |
NCT04077372 -
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
|
N/A | |
Recruiting |
NCT03073785 -
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT03665441 -
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
|
Phase 3 | |
Recruiting |
NCT04627246 -
Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06217666 -
Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)
|
Phase 1 | |
Recruiting |
NCT05585320 -
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT04119362 -
PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer
|
||
Completed |
NCT03105921 -
Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma
|
N/A | |
Not yet recruiting |
NCT05287347 -
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
|